Shanghai Medicilon Inc.

  In the field of   immunotherapy , CD73, an immune regulatory molecule, has attracted much attention in recent years.  As an important component of the tumor microenvironment, CD73 plays an important role in regulating immune responses, inhibiting immune cell activity, and promoting tumor growth and angiogenesis.  Targeted therapy against CD73 has become a target pursued by researchers.  Recently, the ADC project HB0052 of Shanghai Huaota Biopharmaceutical Co., Ltd. (hereinafter referred to as "Huaota") was approved by the FDA to enter clinical trials. Huaota has long been focused on the research, development and production of new biological drugs in the fields of tumors, autoimmune diseases and fundus lesions.  The company has a rich product pipeline and currently has more than 20 research projects, many of which have entered the clinical research stage and are undergoing clinical trials in the United States, New Zealand and China.  What competitiven...

  In 1893, William Coley, a New York orthopedic surgeon, accidentally discovered that postoperative streptococcus pyogenes infection caused tumor regression in patients with sarcoma, which opened the prelude to immunotherapy.  After countless explorations, although immunotherapy has added milestones one after another to the history of human anti-cancer, this marathon is far from reaching the end.  In 2018, under the era of great changes in the China medical system and investment environment, Dr. Xin Dong believes that immunotherapy will set off a new revolution and bring infinite possibilities to life.  Dr. Dong founded Neologics Bioscience (Neologics) and committed to the development of "global new" R&D pipelines for the immune regulation mechanism of anti-tumor and inflammation based on innovation.  In May of this year, the IND application for NB002, the first new drug of Neologics, was approved by the FDA for clinical approval, successfully taking a key s...